ArticleNature immunology2021
Intravenous nanoparticle vaccination generates stem-like TCF1
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 199 citations in OpenAlex.
- Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026Review
- Metal-organic framework nanovaccines for systemic tumour regression.Nature biomedical engineering · 2026Article
- Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8Molecular therapy. Oncology · 2026Article
- Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.Vaccines · 2026Review
- Programming the immunological properties of mRNA vaccines for cancer.Nature reviews. Immunology · 2026Review
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Spatiotemporal dynamics of adoptively transferred stem-like CD8bioRxiv : the preprint server for biology · 2026Article
- Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic.Journal for immunotherapy of cancer · 2026Article
- The promises and challenges of neoantigen cancer vaccines.Nature biotechnology · 2026Review
- PD-1 antibody-bound progenitor-exhausted CD8Nature communications · 2026Article
- Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8Research square · 2026Article
- Oral immunization withJournal for immunotherapy of cancer · 2026Article
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting.Frontiers in immunology · 2026Review
- Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Signal transduction and targeted therapy · 2025Article
- Omics-enhanced nanomedicine: integrating multi-omics for precision cancer diagnosis and therapy.Discover oncology · 2025Review
- Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Progress in cancer vaccines enabled by nanotechnology.Nature nanotechnology · 2025Review
- Tumor-derived small extracellular vesicles loaded with functionally active miR-34a mimic can modify the anti-tumor response in 4T1 breast cancer animal model.Cancer cell international · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 4 countries.
Faezzah BaharomVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ramiro A Ramirez-ValdezVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kennedy K S TobinVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Hidehiro YamaneVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Charles-Antoine DutertreSingapore Immunology Network, A*STAR, Singapore, Singapore.
Ahad KhalilnezhadSingapore Immunology Network, A*STAR, Singapore, Singapore.
Glennys V ReynosoViral Immunity and Pathogenesis Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Vincent L CobleAvidea Technologies, Baltimore, MD, USA.
Geoffrey M LynnAvidea Technologies, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9653-6691
Matthew P MulèSystems Genomics and Bioinformatics Unit, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Andrew J MartinsSystems Genomics and Bioinformatics Unit, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
John P FinniganDepartment of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.
Xiao Meng ZhangSingapore Immunology Network, A*STAR, Singapore, Singapore.
Jessica A HamermanImmunology Program, Benaroya Research Institute, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5864-5299
Nina BhardwajDepartment of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.
John S TsangSystems Genomics and Bioinformatics Unit, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Heather D HickmanViral Immunity and Pathogenesis Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4168-4894
Florent GinhouxSingapore Immunology Network, A*STAR, Singapore, Singapore.ORCID http://orcid.org/0000-0002-2857-7755
Andrew S IshizukaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3024-7536
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. rseder@nih.gov.ORCID http://orcid.org/0000-0003-3133-0849
National Institutes of Health · USAgency for Science, Technology and Research · SGAvidea Technologies (United States) · USTisch Cancer InstituteBenaroya Research Institute
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MIntegrative analysis and modeling of human immune responses and pathologiesZIAAI001152 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TSANG, JOHN · 2011 to 2022
$14.1MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MImaging Antiviral ImmunityZIAAI001225 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HICKMAN, HEATHER · 2017 to 2025
$11.4MFactors Regulating T Helper Cell Memory DifferentiationZ01AI005018 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI SEDER, ROBERT A · 2002 to 2008
$1.2MIntramural NIH HHS Z01 AI005018Intramural NIH HHS ZIA AI001152NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM136577
Abstract
Personalized cancer vaccines are a promising approach for inducing T cell immunity to tumor neoantigens. Using a self-assembling nanoparticle vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a), we show how the route and dose alter the magnitude and quality of neoantigen-specific CD8
Indexed as
NanoparticlesAnimalsAntigen PresentationAntigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesDendritic CellsFemaleHepatocyte Nuclear Factor 1-alphaImmunity, InnateMiceMice, Inbred C57BLVaccinationAntigens, NeoplasmCancer VaccinesHepatocyte Nuclear Factor 1-alphaHnf1a protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.